Front Nutr 2025. Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review (PMID 40959699).
Rationale
Lion's mane is sold as a "brain mushroom", yet the human literature is scattered: isolated small RCTs, pilots, lab work. This is the first PRISMA review pooling all clinical H. erinaceus data with bias-risk assessment (ROBIS) — a real attempt to answer "what is proven vs what is marketing".
Methods
- PubMed search 2000–06/2024 per PRISMA; PROSPERO registration (CRD42024571250).
- Quality control with the ROBIS tool.
- Included: 5 RCTs, 3 pilot clinical trials, 15 laboratory studies, 1 cohort study, 1 case report, 1 computational analysis.
- Topics: cognition, mood, SCFA-producing microbiota, neural stimulation, safety.
What the review gathered
- Cognition: modest positive signals in older adults with MCI and in healthy adults — but short courses (4–16 weeks), small n, heterogeneous extract forms (fruiting body vs erinacine-enriched mycelium).
- Mood: isolated positive studies in mild anxiety/depression — again, small samples.
- Microbiota: data on SCFA-producing bacteria growth — mostly laboratory and pilot work.
- Safety: side effects rare and mild (GI discomfort); no serious signals in the clinical data.
Caveats
- The review confirms the overall picture of our lion's mane card series: interesting signals exist, "miracle" does not. That is not a refutation of benefit — it is "the evidence is thin so far".
- Heterogeneity of forms (fruiting bodies, mycelium, erinacine-enriched mycelium) is the main methodological noise: effects of different preparations cannot be lumped together.
- Null results (our card
ezhovik-working-memory-young-adults-2022, PMID 40276537) fit the review picture: acute and short interventions give weak or zero response. - The practical takeaway: at the current evidence level lion's mane is a reasonably safe supplement with unconfirmed but investigable benefit — not a treatment for cognitive impairment or depression.